Danish biotech firm Bavarian Nordic said Saturday it plans to ramp up production of its mpox vaccine and work with international health organizations to ensure fair access as the disease has been declared a global public health emergency.
The company, one of the few drugmakers with an mpox vaccine, said it has informed the Africa Centers for Disease Control and Prevention (CDC) that it can manufacture 10 million doses of the vaccine by the end of 2025, and could already supply up to 2 million doses this year.
The company said it is expanding its manufacturing network to include Africa and is prepared to work with the Africa CDC and the World Health Organization (WHO) to make the vaccine accessible to all countries.
Earlier this week, the WHO declared mpox a “global public health emergency” for the second time in two years.
The viral infection, which causes purulent lesions and flu-like symptoms, is usually mild but can be fatal. Two strains are spreading in Congo and neighbouring countries: the endemic form of the virus, clade I, and a new variant called clade Ib.
There have been 27,000 cases and more than 1,100 deaths, mostly among children, in Congo since the current outbreak began in January 2023.
